Show
Sort by
-
- Journal Article
- A1
- open access
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer : ALEPRO trial
-
- Miscellaneous
- open access
MultiNicheNet: a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data
(2023) -
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study
-
- Journal Article
- A1
- open access
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma : an ovarian tumor tissue analysis consortium study
-
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
-
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial
(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188 -
- Journal Article
- A1
- open access
Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates
-
A cellular hierarchy in melanoma uncouples growth and metastasis
-
- Journal Article
- A1
- open access
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
-
IL1 beta promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D